Acacia Pharma Ltd
18
0
1
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
5.6%
1 terminated/withdrawn out of 18 trials
94.1%
+7.6% vs industry average
28%
5 trials in Phase 3/4
63%
10 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Role: lead
Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients
Role: lead
Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
Role: lead
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
Role: lead
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Role: lead
European Phase III Study of APD421 in PONV
Role: lead
Mass-balance Study of [14C]-APD421 in Healthy Volunteers
Role: lead
Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
Role: lead
Phase II Dose-ranging Study of APD421 in PONV
Role: lead
US Phase III Study of APD421 in PONV
Role: lead
Study of APD421 as PONV Treatment (Prior Prophylaxis)
Role: lead
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Role: lead
Thorough QT Study of Intravenous Amisulpride
Role: lead
Study of APD421 With and Without Ondansetron
Role: lead
Proof-of-concept (PoC) Study of APD515
Role: lead
Phase II Proof-of-concept Study of APD421
Role: lead
Pilot Study of APD209 in Cancer Cachexia
Role: lead
Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
Role: lead
All 18 trials loaded